[vc_row][vc_column][vc_column_text css=”.vc_custom_1653489742103{margin-bottom: 0px !important;}”]Which drug patents are expiring in 2023? how about 2024? and 2025?
There are about a dozen websites on the internet answering this very question. We can definitely do better than that. How about the list of drugs that are going off-patent in 2026? Much better. Don’t you like to stay a step ahead of your competitors! We get you.
With the huge growth in the generic drug market, there is no doubt that generic companies (hey there!) are searching for drugs with a soon-to-be-expired label. To make their (your) work easy, we collected not just the drug names, but also included other information like yearly sales, treatment, ingredients, and the disease they cure which could help them (you) easily choose the drug most profitable to develop a generic version 4 years in advance.
So, without any delay, here is the list of drug patents expiring in 2026. Thank us later!
The article has a list of drug patents in 2026. You can get the drug patents expiration list from 2026 to 2030 in a PDF by filling out the form below.
[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][mk_fancy_title color=”#2878bf” size=”32″ line_height=”80″ font_weight=”bolder” txt_transform=”uppercase” margin_bottom=”0″ font_family=”none”]Drug Patents Expiring in 2026[/mk_fancy_title][mk_divider margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Avycaz
Ceftazidime / Avibactam[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7112592 | January 7, 2026 |
| US8471025 | August 12, 2031 |
| US9284314 | June 15, 2032 |
| US9695122 | June 15, 2032 |
| US8969566 | June 15, 2032 |
[/mk_table][vc_column_text css=”.vc_custom_1653289608851{margin-bottom: 0px !important;}”]Dosage: Intravenous infusion
Company: Allergan
Ingredients: AVIBACTAM SODIUM; CEFTAZIDIME
Treatment: Intra-abdominal Infections, Urinary Tract Infections, and Pneumonia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Tavalisse
Fostamatinib[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8211889 | January 19, 2026 |
| US7538108 | March 28, 2026 |
| US7989448 | June 12, 2026 |
| US8163902 | June 17, 2026 |
| US7449458 | September 4, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653291303561{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Rigel Pharmaceuticals
Ingredients: FOSTAMATINIB DISODIUM
Treatment: Chronic Immune Thrombocytopenia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Bridion
Sugammadex[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| USRE44733 | January 27, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653291406718{margin-bottom: 0px !important;}”]Dosage: Intravenous
Company: Merck & Co., Inc
Ingredients: SUGAMMADEX SODIUM
Treatment: Reversal of Neuromuscular Blockade Induced by Rocuronium[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Briviact
Brivaracetam[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6911461 | February 21, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653291482934{margin-bottom: 0px !important;}”]Dosage: Oral, Intravenous
Company: UCB Group
Ingredients: BRIVARACETAM
Treatment: Partial-onset Seizures in People 1 month of age and older[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Procoralan
Ivabradine[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7361650 | February 22, 2026 |
| US7361649 | February 22, 2026 |
| US7879842 | February 22, 2026 |
| US7867996 | December 12, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653291600694{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Servier
Ingredients: IVABRADINE
Treatment: Symptomatic Management of Stable Heart-related Chest Pain and Heart Failure[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Pradaxa
Dabigatran[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7932273 | March 7, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653291674582{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Boehringer Ingelheim
Ingredients: DABIGATRAN ETEXILATE MESYLATE
Treatment: Blood clots, Stroke[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Ozempic
Semaglutide[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8536122 | March 20, 2026 |
| US8129343 | December 5, 2031 |
[/mk_table][vc_column_text css=”.vc_custom_1653291757690{margin-bottom: 0px !important;}”]Dosage: Oral, Subcutaneous
Company: Novo Nordisk
Ingredients: SEMAGLUTIDE
Treatment: Type 2 Diabetes [/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Byetta
Exenatide[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6515117 | April 4, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653291819277{margin-bottom: 0px !important;}”]Dosage: Subcutaneous
Company: AstraZeneca
Ingredients: EXENATIDE SYNTHETIC
Treatment: Type 2 Diabetes [/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Rexulti
Brexpiprazole[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7888362 | April 12, 2026 |
| USRE48059 | December 23, 2028 |
[/mk_table][vc_column_text css=”.vc_custom_1653291915852{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Otsuka America Pharmaceutical
Ingredients: BREXPIPRAZOLE
Treatment: Schizophrenia, Major Depressive Disorder[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Aveed
Nebido[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US11179402 | April 14, 2026 |
| US10617696 | April 12, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1653292009278{margin-bottom: 0px !important;}”]Dosage: Oral, Intramuscular injection
Company: Endo Pharmaceuticals
Ingredients: TESTOSTERONE UNDECANOATE
Treatment: Low Testosterone Levels in Men[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Aptiom
Eslicarbazepine acetate[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US9206135 | April 21, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653292087218{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Sumitomo Pharma Co
Ingredients: ESLICARBAZEPINE ACETATE
Treatment: Partial-onset Seizures Epilepsy[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Vocabria
Cabotegravir[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8410103 | April 28, 2026 |
| US10927129 | April 28, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653292176664{margin-bottom: 0px !important;}”]Dosage: Oral, Intramuscular Injection
Company: ViiV Healthcare
Ingredients: CABOTEGRAVIR
Treatment: HIV/AIDS[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Jevtana
Cabazitaxel[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7241907 | June 10, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653292259837{margin-bottom: 0px !important;}”]Dosage: Intravenous
Company: Sanofi-aventis
Ingredients: CABAZITAXEL
Treatment: Metastatic Castration-resistant Prostate Cancer[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row]
[vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Voltaren
Diclofenac[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8097651 | June 16, 2026 |
| US7759394 | June 16, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653292348074{margin-bottom: 0px !important;}”]Dosage: Oral, Rectal, Intramuscular, Intravenous, Topical
Company: GSK
Ingredients: DICLOFENAC POTASSIUM
Treatment: Inflammatory Diseases such as Gout[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Trintellix
Vortioxetine[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7144884 | June 17, 2026 |
| US8722684 | June 30, 2031 |
[/mk_table][vc_column_text css=”.vc_custom_1653292429322{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Takeda Pharmaceuticals
Ingredients: VORTIOXETINE HYDROBROMIDE
Treatment: Major Depressive Disorder[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Zelboraf
Vemurafenib[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8143271 | June 21, 2026 |
| US7504509 | October 22, 2026 |
| US7863288 | June 20, 2029 |
| US8741920 | July 27, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1653292550910{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Genentech
Ingredients: VEMURAFENIB
Treatment: Late-stage Melanoma[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Rhopressa
Netarsudil[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8450344 | July 11, 2026 |
| US9096569 | July 11, 2026 |
| US10174017 | January 27, 2030 |
| US10654844 | January 27, 2030 |
| US8394826 | November 10, 2030 |
| US9931336 | March 14, 2034 |
| US10588901 | March 14, 2034 |
| US9415043 | March 14, 2034 |
[/mk_table][vc_column_text css=”.vc_custom_1653292699011{margin-bottom: 0px !important;}”]Dosage: Eye drops, Topical
Company: Aerie Pharmaceuticals
Ingredients: NETARSUDIL MESYLATE
Treatment: Glaucoma[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Gilotrif
Afatinib[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| USRE43431 | July 13, 2026 |
| US8426586 | April 10, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1653292919650{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Boehringer Ingelheim
Ingredients: AFATINIB DIMALEATE
Treatment: Non-small Cell Lung Carcinoma[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Beleodaq
Belinostat[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6888027 | August 10, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653292992651{margin-bottom: 0px !important;}”]Dosage: Intravenous
Company: Acrotech Biopharma LLC
Ingredients: BELINOSTAT
Treatment: Hematological Malignancies and Solid Tumors[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Cometriq
Cabozantinib[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7579473 | August 14, 2026 |
| US11091439 | January 15, 2030 |
| US8877776 | October 8, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1653293091340{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Exelixis, Inc
Ingredients: CABOZANTINIB S-MALATE
Treatment: Medullary Thyroid Cancer, Renal Cell Carcinoma, and Hepatocellular Carcinoma[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Isturisa
Osilodrostat[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8835646 | August 23, 2026 |
| US8314097 | March 27, 2029 |
| US9434754 | January 13, 2031 |
[/mk_table][vc_column_text css=”.vc_custom_1653293172872{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Recordati Rare Diseases Inc
Ingredients: OSILODROSTAT PHOSPHATE
Treatment: Cushing’s Disease[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Samsca
Tolvaptan[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8501730 | September 1, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653293240354{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Otsuka America Pharmaceutical
Ingredients: TOLVAPTAN
Treatment: Hyponatremia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sprycel
Dasatinib[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7491725 | September 28, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653293319440{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Bristol-Myers Squibb
Ingredients: DASATINIB
Treatment: Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Aklief
Trifarotene[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7807708 | October 1, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653293394594{margin-bottom: 0px !important;}”]Dosage: Topical
Company: Galderma Laboratories
Ingredients: TRIFAROTENE
Treatment: Acne Vulgaris[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Symproic
Naldemedine[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| USRE46375 | October 5, 2026 |
| USRE46365 | January 11, 2028 |
| US9108975 | November 11, 2031 |
| US10952968 | May 13, 2033 |
[/mk_table][vc_column_text css=”.vc_custom_1653293490928{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Shionogi & Co
Ingredients: NALDEMEDINE TOSYLATE
Treatment: Opioid-induced Constipation[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row]
[vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Saphris
Asenapine[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7741358 | October 6, 2026 |
| US8022228 | October 6, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653293586743{margin-bottom: 0px !important;}”]Dosage: Sublingual
Company: Merck Sharp & Dohme
Ingredients: ASENAPINE MALEATE
Treatment: Schizophrenia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Uptravi
Selexipag[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7205302 | October 31, 2026 |
| US8791122 | August 1, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1653293661984{margin-bottom: 0px !important;}”]Dosage: Oral, intravenous
Company: Actelion Pharmaceuticals
Ingredients: SELEXIPAG
Treatment: Pulmonary Arterial Hypertension[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Bevyxxa
Betrixaban[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7598276 | November 8, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653293734434{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Portola Pharmaceuticals, Inc
Ingredients: BETRIXABAN
Treatment: Venous Thrombosis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Orkambi
Lumacaftor / Ivacaftor[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US9216969 | November 8, 2026 |
| US10597384 | December 4, 2028 |
| US8507534 | September 20, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1653293815050{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Vertex Pharmaceuticals
Ingredients: IVACAFTOR; LUMACAFTOR
Treatment: Cystic Fibrosis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Eliquis
Apixaban[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6967208 | November 21, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653293893672{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Bristol-Myers Squibb
Ingredients: APIXABAN
Treatment: Blood Clots[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Calquence
Acalabrutinib[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7459554 | November 24, 2026 |
| US9290504 | July 11, 2032 |
| US9796721 | July 1, 2036 |
[/mk_table][vc_column_text css=”.vc_custom_1653293979652{margin-bottom: 0px !important;}”]Dosage: Oral
Company: AstraZeneca
Ingredients: ACALABRUTINIB
Treatment: Non-Hodgkin Lymphoma, Mantle Cell Lymphoma [/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sirturo
Bedaquiline[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7498343 | December 1, 2026 |
| US8546428 | March 19, 2029 |
[/mk_table][vc_column_text css=”.vc_custom_1653294060872{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Janssen Therapeutics
Ingredients: BEDAQUILINE FUMARATE
Treatment: Multi-drug-resistant Tuberculosis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Adempas
Riociguat[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7173037 | December 4, 2026 |
| US10662188 | February 18, 2034 |
| US11203593 | February 18, 2034 |
[/mk_table][vc_column_text css=”.vc_custom_1653294160397{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Bayer
Ingredients: RIOCIGUAT
Treatment: Pulmonary Hypertension[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Moxatag
Amoxicillin[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8778924 | December 8, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653294287578{margin-bottom: 0px !important;}”]Dosage: Oral, intravenous
Company: Pragma Pharmaceuticals
Ingredients: AMOXICILLIN
Treatment: Bacterial Infections[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Inrebic
Fedratinib[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7528143 | December 16, 2026 |
| US7825246 | December 16, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1653294386998{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Impact Biomedicines
Ingredients: FEDRATINIB HYDROCHLORIDE
Treatment: Myeloproliferative[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Imbruvica
Ibrutinib[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8697711 | December 28, 2026 |
| US9181257 | December 28, 2026 |
| US8957079 | December 28, 2026 |
| US8735403 | December 28, 2026 |
| US7514444 | December 28, 2026 |
| US8008309 | November 13, 2027 |
| US10125140 | June 3, 2033 |
| US9725455 | June 3, 2033 |
| US10106548 | June 3, 2033 |
| US9296753 | October 30, 2033 |
[/mk_table][vc_column_text css=”.vc_custom_1653294547826{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Janssen Biotech
Ingredients: IBRUTINIB
Treatment: Chronic Lymphocytic Leukemia [/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Kalydeco
Ivacaftor[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8754224 | December 28, 2026 |
| US7495103 | May 20, 2027 |
[/mk_table][vc_column_text css=”.vc_custom_1653294634910{margin-bottom: 0px !important;}”]Dosage: Oral
Company: Vertex Pharmaceuticals
Ingredients: IVACAFTOR
Treatment: Cystic Fibrosis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1653489652440{margin-bottom: 0px !important;}”]
Conclusion
Don’t you like to be on top of things? Well, so do we. And so, we got our pharma team working round the clock finding drug patents that are expiring 8 years from now. Yes, we like to be avant-garde. So if you want to stay ahead too subscribe to us and get the latest updates on drug patents that are expiring in the coming years!
Authored By: Divya Goyal, Team Lead, Life Science Team.[/vc_column_text][/vc_column][/vc_row]
